Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL Journal Article
| Authors: | Moskowitz, C. H.; Zelenetz, A. D.; Kewalramani, T.; Hamlin, P.; Lessac-Chenen, S.; Houldsworth, J.; Olshen, A.; Chaganti, R.; Nimer, S.; Teruya-Feldstein, J. |
| Article Title: | Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL |
| Abstract: | A number of prognostic factors affect outcome in patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL), including refractory disease and the second-line age-adjusted international prognostic index. In de novo DLBCL, the cell of orgin, as determined by expression microarray analysis or immunohistochemistry (IHC), predicts event-free survival (EFS). We evaluated the cell of origin, as well as other pathologic markers of outcome, on the repeat biopsy specimen of 88 transplantation-eligible patients undergoing ifosfamide, carboplatin, etoposide (ICE) second-line chemotherapy (SLT) followed by high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) to see if were they prognostic in the salvage setting. Pre-treatment clinical factors were well balanced between the cohorts. There was no significant difference in response to SLT, HDT, event-free or overall survival based on the cell of origin or any of the common pathologic markers examined. The cell of origin as determined by IHC does not predict outcome in transplantation-eligible patients with relapsed or primary refractory DLBCL. © 2005 by The American Society of Hematology. |
| Keywords: | immunohistochemistry; cancer chemotherapy; cancer survival; controlled study; human tissue; treatment outcome; aged; disease-free survival; middle aged; major clinical study; salvage therapy; disease classification; drug megadose; carboplatin; cohort studies; etoposide; tumor markers, biological; cohort analysis; recurrence; autologous stem cell transplantation; stem cell transplantation; prediction; biopsy; ifosfamide; b cell lymphoma; germinal center; lymphoma, b-cell; predictive value of tests; recurrent disease; tissue array analysis; large cell lymphoma; tissue microarray; transplantation, autologous; lymphoma, large-cell, diffuse |
| Journal Title: | Blood |
| Volume: | 106 |
| Issue: | 10 |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2005-11-15 |
| Start Page: | 3383 |
| End Page: | 3385 |
| Language: | English |
| DOI: | 10.1182/blood-2005-04-1603 |
| PUBMED: | 16091454 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 40" - "Export Date: 24 October 2012" - "CODEN: BLOOA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work